189 related articles for article (PubMed ID: 19188183)
1. Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib.
Jilaveanu L; Zito C; Lee SJ; Nathanson KL; Camp RL; Rimm DL; Flaherty KT; Kluger HM
Clin Cancer Res; 2009 Feb; 15(3):1076-85. PubMed ID: 19188183
[TBL] [Abstract][Full Text] [Related]
2. Expression of drug targets in patients treated with sorafenib, carboplatin and paclitaxel.
Jilaveanu LB; Zhao F; Zito CR; Kirkwood JM; Nathanson KL; D'Andrea K; Wilson M; Rimm DL; Flaherty KT; Lee SJ; Kluger HM
PLoS One; 2013; 8(8):e69748. PubMed ID: 23936348
[TBL] [Abstract][Full Text] [Related]
3. Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenib.
Wilson MA; Zhao F; Letrero R; D'Andrea K; Rimm DL; Kirkwood JM; Kluger HM; Lee SJ; Schuchter LM; Flaherty KT; Nathanson KL
Clin Cancer Res; 2014 Jun; 20(12):3328-37. PubMed ID: 24714776
[TBL] [Abstract][Full Text] [Related]
4. A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel.
Flaherty KT; Schiller J; Schuchter LM; Liu G; Tuveson DA; Redlinger M; Lathia C; Xia C; Petrenciuc O; Hingorani SR; Jacobetz MA; Van Belle PA; Elder D; Brose MS; Weber BL; Albertini MR; O'Dwyer PJ
Clin Cancer Res; 2008 Aug; 14(15):4836-42. PubMed ID: 18676756
[TBL] [Abstract][Full Text] [Related]
5. Glutamatergic pathway targeting in melanoma: single-agent and combinatorial therapies.
Lee HJ; Wall BA; Wangari-Talbot J; Shin SS; Rosenberg S; Chan JL; Namkoong J; Goydos JS; Chen S
Clin Cancer Res; 2011 Nov; 17(22):7080-92. PubMed ID: 21844014
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma: SWOG S0512.
Bhatia S; Moon J; Margolin KA; Weber JS; Lao CD; Othus M; Aparicio AM; Ribas A; Sondak VK
PLoS One; 2012; 7(11):e48787. PubMed ID: 23226204
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy.
Augustine CK; Toshimitsu H; Jung SH; Zipfel PA; Yoo JS; Yoshimoto Y; Selim MA; Burchette J; Beasley GM; McMahon N; Padussis J; Pruitt SK; Ali-Osman F; Tyler DS
Mol Cancer Ther; 2010 Jul; 9(7):2090-101. PubMed ID: 20571072
[TBL] [Abstract][Full Text] [Related]
8. Sorafenib in lung cancer: clinical developments and future directions.
Blumenschein G
J Thorac Oncol; 2008 Jun; 3(6 Suppl 2):S124-7. PubMed ID: 18520294
[TBL] [Abstract][Full Text] [Related]
9. Molecular determinants of melanoma malignancy: selecting targets for improved efficacy of chemotherapy.
Yang J; Zaja-Milatovic S; Thu YM; Lee F; Smykla R; Richmond A
Mol Cancer Ther; 2009 Mar; 8(3):636-47. PubMed ID: 19276165
[TBL] [Abstract][Full Text] [Related]
10. Everolimus augments the effects of sorafenib in a syngeneic orthotopic model of hepatocellular carcinoma.
Piguet AC; Saar B; Hlushchuk R; St-Pierre MV; McSheehy PM; Radojevic V; Afthinos M; Terracciano L; Djonov V; Dufour JF
Mol Cancer Ther; 2011 Jun; 10(6):1007-17. PubMed ID: 21487053
[TBL] [Abstract][Full Text] [Related]
11. Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma.
Flaherty KT; Lee SJ; Zhao F; Schuchter LM; Flaherty L; Kefford R; Atkins MB; Leming P; Kirkwood JM
J Clin Oncol; 2013 Jan; 31(3):373-9. PubMed ID: 23248256
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma.
Davies MA; Fox PS; Papadopoulos NE; Bedikian AY; Hwu WJ; Lazar AJ; Prieto VG; Culotta KS; Madden TL; Xu Q; Huang S; Deng W; Ng CS; Gupta S; Liu W; Dancey JE; Wright JJ; Bassett RL; Hwu P; Kim KB
Clin Cancer Res; 2012 Feb; 18(4):1120-8. PubMed ID: 22223528
[TBL] [Abstract][Full Text] [Related]
13. Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma.
Wilson MA; Zhao F; Khare S; Roszik J; Woodman SE; D'Andrea K; Wubbenhorst B; Rimm DL; Kirkwood JM; Kluger HM; Schuchter LM; Lee SJ; Flaherty KT; Nathanson KL
Clin Cancer Res; 2016 Jan; 22(2):374-82. PubMed ID: 26307133
[TBL] [Abstract][Full Text] [Related]
14. Metastatic melanoma: scientific rationale for sorafenib treatment and clinical results.
Egberts F; Kahler KC; Livingstone E; Hauschild A
Onkologie; 2008 Jul; 31(7):398-403. PubMed ID: 18596389
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer.
Pölcher M; Eckhardt M; Coch C; Wolfgarten M; Kübler K; Hartmann G; Kuhn W; Rudlowski C
Cancer Chemother Pharmacol; 2010 May; 66(1):203-7. PubMed ID: 20204367
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies.
Eisen T; Marais R; Affolter A; Lorigan P; Robert C; Corrie P; Ottensmeier C; Chevreau C; Chao D; Nathan PD; Jouary T; Harries M; Negrier S; Montegriffo E; Ahmad T; Gibbens I; James MG; Strauss UP; Prendergast S; Gore ME
Br J Cancer; 2011 Jul; 105(3):353-9. PubMed ID: 21750549
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma.
Escudier B; Lassau N; Angevin E; Soria JC; Chami L; Lamuraglia M; Zafarana E; Landreau V; Schwartz B; Brendel E; Armand JP; Robert C
Clin Cancer Res; 2007 Mar; 13(6):1801-9. PubMed ID: 17363536
[TBL] [Abstract][Full Text] [Related]
18. Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438).
Margolin KA; Moon J; Flaherty LE; Lao CD; Akerley WL; Othus M; Sosman JA; Kirkwood JM; Sondak VK
Clin Cancer Res; 2012 Feb; 18(4):1129-37. PubMed ID: 22228638
[TBL] [Abstract][Full Text] [Related]
19. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.
Azad NS; Posadas EM; Kwitkowski VE; Steinberg SM; Jain L; Annunziata CM; Minasian L; Sarosy G; Kotz HL; Premkumar A; Cao L; McNally D; Chow C; Chen HX; Wright JJ; Figg WD; Kohn EC
J Clin Oncol; 2008 Aug; 26(22):3709-14. PubMed ID: 18669456
[TBL] [Abstract][Full Text] [Related]
20. C-Raf is associated with disease progression and cell proliferation in a subset of melanomas.
Jilaveanu LB; Zito CR; Aziz SA; Conrad PJ; Schmitz JC; Sznol M; Camp RL; Rimm DL; Kluger HM
Clin Cancer Res; 2009 Sep; 15(18):5704-13. PubMed ID: 19737955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
